CLASSYS Inc (214150) Fair Value & Analysis
Healthcare · KR · Market cap 2.9T KRW
Fair value as of: Jul 17, 2026
From 24 valuation models · updated 23 days ago
Fair value updated Jul 17, 2026, revised from 21,836 KRW to 21,862 KRW (+0.1%) since Jul 7, 2026. Share price −3.6% over the past month.
A strong business, but screening 52% overvalued on our models.
What matters now
- A high-quality business (quality 75/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The model range is unusually wide (16,140 KRW to 87,449 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range 13,112 KRW – 75,600 KRW · fair‑value band 16,140 KRW – 87,449 KRW · the 45,900 KRW price screens above the 21,862 KRW fair value. Dashed = 300-day average. As of Jul 17, 2026.
Analysis
CLASSYS Inc (214150) currently trades at 45,900 KRW, while our model-based Fair Value estimate is 21,862 KRW, implying the stock looks roughly 52.4% overvalued today. The Quality Score stands at 75/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, CLASSYS Inc generated revenue of 347B KRW at a net margin of 39.1%. Revenue grew 13.0% year over year. It earns a return on equity of 27.2%. Net debt stands at 49.0B KRW. Fundamentals as of Jul 17, 2026
Our scenario range runs from 16,140 KRW (bear case) to 87,449 KRW (bull case); at 45,900 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 41% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -52%, 214150 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (80,218 KRW) versus Asset-Based (5,681 KRW). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 74 · Market factors (momentum, volatility) 24
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
CLASSYS Inc. provides medical aesthetics devices worldwide. The company offers ULTRAFORMER MPT, a solution for eyebrow lifting; ULTRAFORMER III, an ultrasound surgical device used for tissue coagulation in eyelid lifting, and for skin tightening and improving subcutaneous tissue elasticity in the face (cheeks), abdomen, and thighs; VOLNEWMER, a monopolar …
Full company description
CLASSYS Inc. provides medical aesthetics devices worldwide. The company offers ULTRAFORMER MPT, a solution for eyebrow lifting; ULTRAFORMER III, an ultrasound surgical device used for tissue coagulation in eyelid lifting, and for skin tightening and improving subcutaneous tissue elasticity in the face (cheeks), abdomen, and thighs; VOLNEWMER, a monopolar radiofrequency therapeutic equipment used to coagulate skin tissue; Secret RF, a device that delivers radio frequency energy into the skin; Secret PRO, a multiple fractional device that delivers micro-level laser beams fractionally to the tissue; Secret DUO, a multi-functional device that delivers high-frequency energy through needle electrodes; and Fortra, a 4 wavelengths diode laser. It also provides SCIZER and CLATUU Alpha for non-invasive subcutaneous fat reduction; Ulfit, a medical device used to improve skin elasticity and subcutaneous tissue in the abdomen and thighs; Refit, a medical device that uses RF and negative pressure to increase tissue temperature and blood flow, relieving pain in the treated area; AQUAPURE, a combination of four handpieces used for acne suction, muscle pain relief, and other pain relief; FORSHAPE, an RF treatment system used to increase metabolism, blood circulation, and tissue recovery; and INTRASURE for lifting, wrinkle reduction, body contouring, and cellulite reduction. In addition, the company offers AQUAPURE II, which exfoliates hyper-keratinized dead skin cells; Reepot, a medical device that delivers energy to tissue; veloce, which enhances treatment results; Pento, a laser surgical device for tissue incision, destruction, and removal; and curas hybrid laser system. Further, it sells cosmetics. The company offers its products under the Classys, Cluederm, and Skederm brands. It serves distributors, clinics, hospitals, and direct end users. The company was founded in 2007 and is headquartered in Seoul, South Korea. CLASSYS Inc. is a subsidiary of BCPE Centur Investments, LP.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
CLASSYS Inc reported revenue of 337B KRW in FY2025 versus 101B KRW in FY2021, a compound +35.3%/yr. Reported net income was 132B KRW in FY2025, compounding +31.7%/yr from FY2021.
214150 screens 52% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare CLASSYS Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is CLASSYS Inc (214150) overvalued or undervalued?
What is the fair value of 214150?
What is the quality score of 214150?
What is the revenue of CLASSYS Inc (214150)?
What is the net profit margin of 214150?
Does CLASSYS Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track CLASSYS Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.